32. Bewley AP, Shear NH, Calzavara-Pinton PG, et al. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison. J Eur Acad Dermatol Venereol. 2019;33(6):1107-1115.
33. Nyeland ME, Becla L, Patel DS, et al. Calcipotriene plus betamethasone dipropionate (0.005%/0.064%) foam and apremilast: matching-adjusted indirect comparison and US cost per responder analyses. SKIN The Journal of Cutaneous Medicine. 2018;2. doi: https://doi.org/10.25251/skin.2.supp.92.
34. Otezla® (apremilast) [package insert]. Summit, NJ: Celgene Corporation; 2019.
35. Haidari W, Pona A, Feldman SR. Management of residual psoriasis in patients on biologic treatment. J Drugs Dermatol. 2020;19(2):217-223.
36. Armstrong AW, Koning JW, Rowse S, et al. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data. Dermatol Ther (Heidelb). 2017;7(1):97-109.
37. Yeung H, Wan J, Van Voorhees AS, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2013;68(1):64-72.
38. Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180-1185.
39. Veverka KA, Hansen JB, Patel DS, et al. Early improvements in plaque psoriasis clinical response with fixed-combination calcipotriene and betamethasone dipropionate (Cal/BD) foam treatment from the PSO-FAST trial. Presented at: EADV 2019 Congress in Dermatology and Venereology; October, 9-13, 2019; Madrid, Spain.
33. Nyeland ME, Becla L, Patel DS, et al. Calcipotriene plus betamethasone dipropionate (0.005%/0.064%) foam and apremilast: matching-adjusted indirect comparison and US cost per responder analyses. SKIN The Journal of Cutaneous Medicine. 2018;2. doi: https://doi.org/10.25251/skin.2.supp.92.
34. Otezla® (apremilast) [package insert]. Summit, NJ: Celgene Corporation; 2019.
35. Haidari W, Pona A, Feldman SR. Management of residual psoriasis in patients on biologic treatment. J Drugs Dermatol. 2020;19(2):217-223.
36. Armstrong AW, Koning JW, Rowse S, et al. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data. Dermatol Ther (Heidelb). 2017;7(1):97-109.
37. Yeung H, Wan J, Van Voorhees AS, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2013;68(1):64-72.
38. Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180-1185.
39. Veverka KA, Hansen JB, Patel DS, et al. Early improvements in plaque psoriasis clinical response with fixed-combination calcipotriene and betamethasone dipropionate (Cal/BD) foam treatment from the PSO-FAST trial. Presented at: EADV 2019 Congress in Dermatology and Venereology; October, 9-13, 2019; Madrid, Spain.
AUTHOR CORRESPONDENCE
John Koo MD John.Koo2@ucsf.edu
